(Press-News.org) **Various Embargoes**
THE LANCET JOURNALS: Papers being presented at the American Diabetes Association [ADA] 85th Scientific Sessions
The following papers published across The Lancet Group will be presented at the American Diabetes Association [ADA] 85th Scientific Sessions. The conference will take place from Friday 20 June through Monday 23 June 2025 in Chicago, Illinois, USA.
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
Highlighted content:
**Embargo: 00.30 Saturday 21st June [UK time] / 6.30pm [US CT] Friday 20th June 2025** Please note the unusual embargo time.
Peer-reviewed / Randomised Controlled Trial x2 / People
The Lancet: Amycretin shows promise as a new weight management therapy, early phase clinical trials confirm
Amycretin, a novel weight management medication, showed promise in two new, early-phase clinical trials published in The Lancet. Amycretin is designed to target two specific receptors in the body — the GLP-1 receptor and the amylin receptor – to help control blood sugar and appetite. Because this medicine can activate both receptors at the same time, researchers say it has the potential to better manage conditions such as overweight and obesity compared to medicines that target just one receptor.
A phase 1b/2a trial tested the safety and tolerability of once-weekly subcutaneous (under the skin and above the muscle) injections of amycretin in 125 adults with overweight or obesity. Participants who received the highest doses (up to 60 mgs) reported body weight reductions of up to 24.3% after 36 weeks of treatment. A high frequency of gastrointestinal adverse effects (including nausea and vomiting) were reported although these were mostly mild to moderate and typically resolved by the end of treatment. The medication also showed signs of improving blood sugar levels, but further trials will be needed to confirm the role of amycretin in this aspect of diabetes management.
The second phase 1 trial investigated oral amycretin taken daily over 12 weeks in 144 participants. This first-in-human trial confirmed amycretin’s safety and tolerability, with mild to moderate gastrointestinal side effects, including loss of appetite, nausea, and vomiting. Participants taking the highest dose (100 mgs per day), of oral amycretin lost an average of 13.1% of their body weight after 12 weeks, suggesting oral amycretin could be a promising weight management medication.
Together, these studies suggest amycretin – both as a once-weekly injection and as a daily oral medication – could be a promising approach for treating overweight, obesity, and type 2 diabetes, though larger studies will be needed to confirm these findings.
In a linked Comment to the two articles, Professor Tricia Tan and Dr Bernard Khoo (who were not involved in the studies), highlight the need to look beyond weight loss in obesity management to understand if treatments reduce the risk of cardiovascular disease and other conditions linked to obesity.
Paper 1 (subcutaneous amycretin) available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/SCAmycretin.pdf
Paper 2 (oral amycretin) available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/OralAmycretin.pdf
Linked comment available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/AmycretinLC.pdf
Paper 1 appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tl3216_Dahl_Appendix.pdf
Paper 2 appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tl0293_appendix.pdf
Once the embargo lifts, please use these links as the one above will be deactivated:
Paper 1 (subcutaneous amycretin): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/fulltext
Paper 2 (oral amycretin): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01176-6/fulltext
For interviews with the authors of both studies, contact:toig@novonordisk.com
-
**Embargo: 20:45 [UK time] / 02:45pm [US CT] Saturday 21st June 2025** Please note the unusual embargo time.
Peer-reviewed / Randomised Controlled Trial / People
The Lancet Diabetes & Endocrinology: Ecnoglutide, a new medication for weight management, is a safe and effective, trial confirms
Ecnoglutide,a novel type of weight loss medication that may help lower blood sugar by targeting a specific receptor in the body, is a safe and effective treatment option for weight management in individuals with overweight or obesity without diabetes, confirms a phase 3 randomised controlled trial (RCT) published in The Lancet Diabetes & Endocrinology journal. The trial found that those taking ecnoglutide lost between 9% and 13% of their body weight on average, after 40 weeks of treatment, compared to almost no weight change in the placebo group, suggesting ecnoglutide is as safe and effective as other currently approved GLP-1 receptor agonists, such as semaglutide or tirzepatide.
Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist that works by primarily activating a singular pathway inside cells—potentially leading to more targeted therapeutic effects (such as improved insulin secretion and reduction in bodyweight). The researchers say it may be more effective than other, similar weight loss medications and is just as safe. While ecnoglutide had shown promise in smaller trials, this is the first phase 3 trial to investigate its efficacy and safety in individuals with overweight or obesity.
The SLIMMER trial involved 664 adults with overweight or obesity without diabetes in China who were randomly assigned to receive a once weekly dose of ecnoglutide (either 1.2, 1.8, or 2.4 mg) or a placebo over 48 weeks. The trial also found that a much higher percentage of people on ecnoglutide lost at least 5% of their body weight compared to those on placebo (77–87% compared to 16%) over 40 weeks of treatment. Ecnoglutide was found to be similarly safe as approved GLP-1 receptor agonists, with the most common side effects being mild to moderate digestive system related issues, like nausea; however, very few people stopped treatment because of side effects.
The authors highlight that those on the higher doses of ecnoglutide continued to experience weight loss up to week 48, indicating that even greater weight loss may be achievable with extended ecnoglutide treatment. They suggest that ecnoglutide may serve as a treatment option for individuals who fail to achieve sufficient weight reduction with existing GLP-1 receptor agonists or need to achieve a more drastic target of body weight reduction.
Article available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/EcnoglutideADA.pdf
Linked comment available under embargo at: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/EcnoglutideADALC.pdf
Appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tlde0300_Appendix.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00141-X/fulltext
For interviews with the authors, please contact: jiln@bjmu.edu.cn
-
For the below additional Lancet content publishing at ADA, please see: https://drive.google.com/drive/folders/1lqTaGPyhN2CiXzdri5WZ2Ux3QpISZgEp?usp=sharing
**Embargo: 19.30 UK time /13.30 pm CT Sunday 22nd June**
Once-weekly insulin efsitora alfa versus once-daily insulin glargine in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a randomised clinical trial
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3 randomised non-inferiority trial
**Embargo: 14.00 UK time / 8.00 am CT Monday 23rd June**
A three paper Series on early-onset type 2 diabetes END
THE LANCET JOURNALS: Papers being presented at the American Diabetes Association [ADA] 85th Scientific Sessions
2025-06-23
ELSE PRESS RELEASES FROM THIS DATE:
Research reveals why receiving food before others is a source of discomfort for social diners
2025-06-23
Restaurants and dinner hosts could improve dining experiences and reduce social awkwardness by serving guests at the same time, a new study has found.
We have all faced that situation in a restaurant or at a dinner party: our food has arrived but we find ourselves waiting for others at the table to be served before starting. This long-established norm is the subject of new research co-authored by Bayes Business School, that shows we are more concerned about violating this practice ourselves than we are about others doing so.
WATCH: Authors of the study explain its outcomes
The ...
Mapping the gaps: New global assessment reveals stark biases in ocean biodiversity data
2025-06-23
Despite decades of ocean exploration, humans still lack basic answers to one of the most fundamental ecological questions: where is marine life found, and why?
A new study published in Communications Earth & Environment, highlights just how uneven our knowledge of ocean biodiversity really is.
By systematically processing nearly 19 million records from the Ocean Biodiversity Information System (OBIS), the study reveals that global marine biodiversity data from below 30m are heavily biased towards shallow waters (50% of benthic records come from just the shallowest 1% of the ...
Penn engineers turn toxic fungus into anti-cancer drug
2025-06-23
Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.
“Fungi gave us penicillin,” says Sherry Gao, ...
International study: AI has little impact on workers’ wellbeing so far, but…
2025-06-23
As artificial intelligence reshapes workplaces worldwide, a new study provides early evidence suggesting AI exposure has not, thus far, caused widespread harm to workers' mental health or job satisfaction. In fact, the data reveals that AI may even be linked to modest improvements in worker physical health, particularly among employees with less than a college degree.
But the authors caution: It is way too soon to draw definitive conclusions.
The paper, “Artificial Intelligence and the Wellbeing of Workers,” published June 23 in Nature: Scientific Reports, uses two decades of longitudinal data from the ...
Scientists develop test that predicts which patients will not respond to cancer chemotherapy
2025-06-23
The use of this test in clinical practice would allow for the avoidance of side effects and the implementation of more effective treatment.
"We've found a way to practice precision medicine with standard chemotherapy," says Geoff Macintyre, a researcher at the Spanish National Cancer Research Centre (CNIO).
The research has been published in the journal Nature Genetics
The test will now be validated in a hospital setting, thanks to a new project funded by the Spanish Ministry for Digital Transformation and Public Service.
Chemotherapy seeks to destroy tumor cells and has been a standard treatment ...
Scientists create test to predict chemotherapy resistance in patients
2025-06-23
Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a test which can successfully predict whether cancer will resist common forms of chemotherapy treatment.
It works by looking at changes to the order, structure and number of copies of DNA within the cancer - known as chromosomal instability (CIN) signatures. These signatures are found by reading the full DNA sequence of the tumour and looking for patterns in how the chromosomes are disrupted when compared to normal cells
The ...
Wildfires threaten water quality for up to eight years after they burn
2025-06-23
Years after wildfires burn forests and watersheds, the contaminants left behind continue to poison rivers and streams across the Western U.S. — much longer than scientists estimated.
A new study, published today in Nature Communications Earth & Environment, analyzed water quality in more than 500 watersheds across the Western U.S., and is the first large-scale assessment of post-wildfire quality.
The research was led by scientists from the Cooperative Institute for Research in Environmental Science ...
More effective production of “green” hydrogen with new combined material
2025-06-23
The chemical reaction to produce hydrogen from water is several times more effective when using a combination of new materials in three layers, according to researchers at Linköping University in Sweden. Hydrogen produced from water is a promising renewable energy source – especially if the hydrogen is produced using sunlight.
The production of new petrol and diesel cars will be banned in the EU as of 2035. Electric motors are expected to become increasingly common in vehicles – but they are not suitable for all types of transport.
“Passenger cars can have a battery, but heavy trucks, ships or aircraft cannot use ...
Study reveals processes important for skin cancer aggressiveness and identifies two classes of drugs that may block them
2025-06-23
Researchers have discovered that the most aggressive melanomas, the deadliest form of skin cancer, overactivate two key processes in mitochondria, the components of cells that provide energy. Blocking these pathways with currently available drugs effectively killed melanoma cells. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
By mapping the proteins expressed in 151 tumor and normal skin samples, investigators found that the most aggressive melanomas hyper-activate the ...
Recycled plastics can affect hormone systems and metabolism
2025-06-23
A single pellet of recycled plastic can contain over 80 different chemicals. A new study with researchers from University of Gothenburg and Leipzig shows that recycled polyethylene plastic can leach chemicals into water causing impacts in the hormone systems and lipid metabolism of zebrafish larvae.
The plastic pollution crisis has reached global levels, threatening both planetary and human health, and recycling is proposed as one of the solutions to the plastics pollution crisis. However, as plastics contain thousands of chemical additives and other substances that can be toxic, and these are almost ...